Loading [MathJax]/jax/output/SVG/jax.js
Review

SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines

  • These authors contributed equally to this work.
  • Received: 15 June 2020 Accepted: 21 July 2020 Published: 23 July 2020
  • All species of coronavirus may cause infections in birds which is known to us since the 60s, but recently, from Nov 2019, the disease emerged in humans from the seafood market in Wuhan city. The previous viral outbreaks like SARS-CoV and MERS-CoV have also shown a greater mortality rate when transmitted to humans than other animals. An emerging concern in the 2019 novel coronavirus (SARS-CoV-2) is in terms of developing vaccine or discovery of new drugs to overcome the current viral pandemic. In this rapid-review, we aim to update the available data on coronavirus with the latest findings and achievements. So far, great steps have been taken such as hrsACE2 by a Swedish team from Karolinska Institute. Monash University announced the efficacy of Ivermectin to overcome COVID-19. The CRISPR/Cas13d as a new innovative therapeutics based might overcome the challenge of COVID-19. those strains of virus which lacking E protein-encoding regions are the perfect choice for vaccine development.

    Citation: Amir Khodavirdipour, Fariba Keramat, Seyed Hamid Hashemi, Mohammad Yousef Alikhani. SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines[J]. AIMS Molecular Science, 2020, 7(3): 281-291. doi: 10.3934/molsci.2020013

    Related Papers:

    [1] Muntaser Safan . Mathematical analysis of an SIR respiratory infection model with sex and gender disparity: special reference to influenza A. Mathematical Biosciences and Engineering, 2019, 16(4): 2613-2649. doi: 10.3934/mbe.2019131
    [2] Majid Jaberi-Douraki, Seyed M. Moghadas . Optimal control of vaccination dynamics during an influenza epidemic. Mathematical Biosciences and Engineering, 2014, 11(5): 1045-1063. doi: 10.3934/mbe.2014.11.1045
    [3] Eunha Shim . Prioritization of delayed vaccination for pandemic influenza. Mathematical Biosciences and Engineering, 2011, 8(1): 95-112. doi: 10.3934/mbe.2011.8.95
    [4] Roy Curtiss III . The impact of vaccines and vaccinations: Challenges and opportunities for modelers. Mathematical Biosciences and Engineering, 2011, 8(1): 77-93. doi: 10.3934/mbe.2011.8.77
    [5] Olivia Prosper, Omar Saucedo, Doria Thompson, Griselle Torres-Garcia, Xiaohong Wang, Carlos Castillo-Chavez . Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza. Mathematical Biosciences and Engineering, 2011, 8(1): 141-170. doi: 10.3934/mbe.2011.8.141
    [6] Lili Liu, Xi Wang, Yazhi Li . Mathematical analysis and optimal control of an epidemic model with vaccination and different infectivity. Mathematical Biosciences and Engineering, 2023, 20(12): 20914-20938. doi: 10.3934/mbe.2023925
    [7] Kai Zhang, Xinwei Wang, Hua Liu, Yunpeng Ji, Qiuwei Pan, Yumei Wei, Ming Ma . Mathematical analysis of a human papillomavirus transmission model with vaccination and screening. Mathematical Biosciences and Engineering, 2020, 17(5): 5449-5476. doi: 10.3934/mbe.2020294
    [8] Salman Safdar, Calistus N. Ngonghala, Abba B. Gumel . Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Mathematical Biosciences and Engineering, 2023, 20(1): 179-212. doi: 10.3934/mbe.2023009
    [9] Sheng-I Chen, Chia-Yuan Wu . A stochastic programming model of vaccine preparation and administration for seasonal influenza interventions. Mathematical Biosciences and Engineering, 2020, 17(4): 2984-2997. doi: 10.3934/mbe.2020169
    [10] Jinliang Wang, Gang Huang, Yasuhiro Takeuchi, Shengqiang Liu . Sveir epidemiological model with varying infectivity and distributed delays. Mathematical Biosciences and Engineering, 2011, 8(3): 875-888. doi: 10.3934/mbe.2011.8.875
  • All species of coronavirus may cause infections in birds which is known to us since the 60s, but recently, from Nov 2019, the disease emerged in humans from the seafood market in Wuhan city. The previous viral outbreaks like SARS-CoV and MERS-CoV have also shown a greater mortality rate when transmitted to humans than other animals. An emerging concern in the 2019 novel coronavirus (SARS-CoV-2) is in terms of developing vaccine or discovery of new drugs to overcome the current viral pandemic. In this rapid-review, we aim to update the available data on coronavirus with the latest findings and achievements. So far, great steps have been taken such as hrsACE2 by a Swedish team from Karolinska Institute. Monash University announced the efficacy of Ivermectin to overcome COVID-19. The CRISPR/Cas13d as a new innovative therapeutics based might overcome the challenge of COVID-19. those strains of virus which lacking E protein-encoding regions are the perfect choice for vaccine development.


    Influenza is an acute respiratory disease caused by influenza viruses, types A, B, C and D, which circulate in all parts of the world. The World Health Organization (WHO) reported that influenza occurs globally with an annual attack rate estimated at 5%10% in adults and 20%30% in children, and these annual epidemics are estimated to result in about 3,000,000 to 5,000,000 cases of severe illness and about 290,000 to 650,000 deaths [1].

    In recent years, ambient air pollution (AAP), contamination of the indoor/outdoor environment by any chemical, physical or biological agent that modifies the natural characteristics of the atmosphere, is one of the greatest environmental risks to health and has become a severe problem across the world. Environmental toxins spread at all levels of biological systems, extending from atoms to biospheres, and they have impacts on cells, organs, organisms, populations and the whole ecosystem. For example, fog and haze can be taken as a proof of air pollution resulting in health problems in big cities, containing harmful toxic substances like sulfur dioxide, nitrogen oxides, etc., invading bodies and causing health damage. WHO estimated in 2019 that ambient (outdoor) air pollution caused 4.2 million premature deaths worldwide, and this mortality is due to exposure to fine particulate matter (PM), which causes cardiovascular and respiratory disease, and cancers [2]. It is reported that particle droplets are considered to be a primary transmission mode for influenza virus infection due to sneezing and coughing [3]. Therefore, contagious PM may cause influenza disease spread [4,5].

    Mathematical modeling approaches in epidemiology have been a great tool to reveal deep understanding of the mechanisms underlying the spread and thus provide effective methods for the control of influenza disease [6,7,8,9,10,11,12]. Recently, some epidemiological studies revealed associations of air pollution with influenza infection. There are reports that PM2.5, PM10, SO2, NO2 and CO are associated with the influenza positivity rate [13,14,15]. Huang et al. [16] investigated the the adverse health effects of air pollution and the cause of influenza-like illness (ILI). Meng et al. [17] observed that air pollution may be associated with the risk of influenza in a broad sense. Lu et al. [18] reported a greater short-term impact on childhood pneumonia from PM1 in comparison to PM2.5 and PM10. Taken together, air pollution could be one of the determinant factors of influenza infection. It should be noted that the results above are based on the statistical analysis. However, it is rare to study the effect of AAP on influenza transmission by a using dynamical model.

    Huaian is located in the ranges of 324300340600 N and 11812001193630 E, in the transition region between the southern warm temperate zone and the northern subtropical zone. Huaian, the central area of northern Jiangsu province, China, is composed of four districts, namely, Qingjiangpu, Huaiyin, Huaian and Hongze, and three counties, namely, Lianshui, Xuyi and Jinhu (see Figure 1). The maximum linear distance between east and west is 132 kilometers, and the maximum linear distance between north and south is 150 kilometers, covering an area of 10.03 thousand square kilometers. By the end of 2021, the permanent population of Huaian was 4.5622 million.

    Figure 1.  The location of Huaian in Jiangsu province, China.

    Beyond all doubt, influenza is an acute epidemic in Huaian, China. The data of reported cases of ILI and the AAP, including PM2.5, PM10, SO2, NO2, O3 and CO, from the 1st week of 2019 to 52nd week of 2019 in Huaian, China, are shown in Figure 2.

    Figure 2.  The weekly reported number of ILI cases and the data of the AAP in Huaian, China, in year 2019.

    Naturally, there comes a question: What is the relation between the incidence of ILI and the AAP?

    The main goal of this paper is to investigate the effect of the AAP on the incidence of ILI in Huaian, China, and to provide some useful strategies to control the spreading of influenza. The rest of the paper is organized as follows: In the following section, we formulate an environmental AAP-dependent SIPS influenza model with partial immunity and vaccination. In Section 3, we study the dynamics of the proposed model, including the positivity and boundedness of the model, equilibrium analysis with basic reproduction number. In Section 4, based on the statistic data, we estimate the parameters of the model, and study controlling the prevalence of influenza in Huaian, China. The last section includes a general discussion and some concluding remarks.

    Suppose that, in the absence of air pollution, the total population N(t) is divided into three parts, the susceptible S(t), the infectious I(t) and the partial immunity P(t), i.e., N(t)=S(t)+I(t)+P(t). Recovered individuals from influenza infection are not permanently immune to the next influenza virus [19]. The influenza model incorporating partial immunity of the recovered individuals and vaccination of the susceptible is presented by the following SIPS model:

    {dSdt=ΛβSINμSϕS+σ(1p)I+γP,dIdt=βSINμIσI,dPdt=ϕS+σpIμPγP. (1)

    The biological meanings of the parameters of model (1) are shown in Table 1.

    Table 1.  Biological interpretations of parameters in models (1) and (4).
    Parameter Description
    Λ Recruitment rate of the population
    m Effect coefficient of the AAP on transmission rate
    μ Natural death rate
    σ Recovery rate
    ϕ Vaccination rate
    α Rate of the vaccine wearing off
    p Probability of the recovered becoming the susceptible
    ρ Uptake coefficient
    ξ Depletion rate of the AAP in the population
    β(t)=b1sin(b2t+b3) Transmission rate from susceptible to infective population
    a(t)=a1+a2sin(π26t+a3) Exogenous input rate of the AAP into the environment
    η(t)=c1sin(π26t) Depuration rate of the AAP in the environment

     | Show Table
    DownLoad: CSV

    To mechanistically incorporate the AAP into the basic SIPS model (1), we apply some of the existing models in this direction [20,21,22,23]. Let E(t) be the concentration of the AAP in the environment, and C(t) is the concentration of the AAP in the population, at time t0, respectively. Assume that the AAP may be externally introduced into the environment according to some prescribed rate a(t). The AAP in the environment is washed out or broken down with time-dependent rate η(t), which may occur if the environment is a lake which on occasion drains into another body of water, or if the AAP is subject to chemical decomposition. Further, we assume that the AAP from the environment is absorbed by the population in direct proportion to its concentration (i.e., ρNE), and the AAP in the population may also be removed from the total environment directly with rate ξ. We apply the term mC(t) to describe the impact of the AAP on the transmission rate, and then the transmission rate becomes

    λ(C):=β(t)(1+mC). (2)

    The schematic diagram is provided in Figure 3 for clear understanding of the model system. Then, we can obtain the extended model as follows:

    {dSdt=Λλ(C)SINμSϕS+σ(1p)I+αP,dIdt=λ(C)SINμIσI,dPdt=ϕS+σpIμPαP,dCdt=ρNEξC,dEdt=a(t)η(t)EρNE. (3)
    Figure 3.  Flow diagram of the influenza transmission routes in a polluted environment.

    The biological meanings of all parameters of model (3) are also shown in Table 1.

    It is true that the amount of the AAP consumed by the population is usually very small in quantity, and hence the term ρNE in the fifth equation in model (3) can be neglected. Then, the research object of this paper is as follows:

    {dSdt=Λλ(C)SINμSϕS+σ(1p)I+αP,dIdt=λ(C)SINμIσI,dPdt=ϕS+σpIμPαP,dCdt=ρNEξC,dEdt=a(t)η(t)E. (4)

    The total population N(t) satisfies the following system:

    dNdt=ΛμN.

    Then,

    limtN(t)=Λμ:=N.

    The initial values of model (4) are:

    S(0)>0,I(0)0,P(0)0,C(0)0,E(0)>0.

    In this subsection, we analyze the positivity and boundedness of model (4) to ensure that the model is well-posed.

    Theorem 1. All solutions of model (4) that start in R5+={(S,I,P,C,E):S>0,I>0,P>0,C0,E>0} remain non-negative for all the time.

    Proof. Since the right hand side of model (4) is continuous and locally Lipschitzian on C (space of continuous functions), the solution (S(t),I(t),P(t)) of model (4) exists and is unique on [0,τ), where 0<τ+ [24]. From the second equation of model (4), we can obtain that

    I(t)=I(0)exp{t0(λ(C)NS(s)(μ+σ))ds},

    which implies that when I(0)>0, I(t)>0 for t>0. Note that I(t) may tend to zero when t. Thus, we put I(t)0. Next, we show that, S(t)>0, t[0,τ). If it does not hold, then t1[0,τ) such that S(t1)=0, dSdt|t=t10 and S(t)>0,t[0,t1). So, there must be P(t)>0,t[0,t1). Suppose the statement is not true. Then, t2[0,t1) such that P(t2)=0, dPdt|t=t20 and P(t)>0,t[0,t2). From the third equation of (4), we get

    dPdt|t=t2=ϕS(t2)+σpI(t2)>0,

    which is a contradiction to dPdt|t=t20. So, V>0,t[0,t1). Following from the first equation of (4), we have

    dSdt|t=t1=Λ+σ(1p)I(t1)+αP(t1)>0,

    which is a contradiction to dSdt|t=t10. It shows that S(t)>0, t[0,τ).

    Next, we claim C(t)0, t[0,τ). Otherwise, t3[0,τ) such that C(t3)=0, dCdt|t=t3<0 and C(t)0,t[0,t3). Hence, there must be E(t)0,t[0,t3). If this statement is not true, then t4[0,t3) such that E(t3)=0, dEdt|t=t3<0 and E(t)0,t[0,t4). From the fifth equation of (4), we get

    dEdt|t=t4a(t)0,

    which is a contradiction to dEdt|t=t2<0. So, E0,t[0,t3). Following from the fourth equation of (4), we have

    dCdt|t=t3=ρNE(t3)0,

    which is a contradiction to dCdt|t=t3<0. It shows that C(t)0, t[0,τ). Therefore,

    S(t),V(t)>0,I(t)0,C(t),E(t)0,t0.

    This completes the proof.

    It is easy to know that, for model

    {dEdt=a(t)η(t)E(t),t>0,E(0)=E0, (5)

    there is a unique continuous periodic solution E(t) which is globally asymptotically stable, where

    E(t)=exp{t0η(s)ds}(E0+t0a(s)exp{s0η(τ)dτ}ds). (6)

    The study of the dynamics of model (4) requires the introduction of the following set:

    Γ={(S,I,V,C,E)R5+:0<S+I+VΛμ,0<CˆC,0<EˆE},

    where ˆE=supt[0,ω)E(t),ˆC=ρΛˆEμξ. Γ is a positive invariant set for model (4).

    When the disease dies out, we can get the following system from model (4):

    {dSdt=ΛμSϕS+αP,dPdt=ϕSμPαP,dCdt=ρ(S+P)E(t)ξC. (7)

    Then, model (7) with initial condition (S(0),P(0),C(0)) has a unique positive ω-periodic solution u(t)=(S,P,C(t)), where

    S=Λ(μ+α)μ(α+μ+ϕ),P=Λϕμ(α+μ+ϕ),C(t)=C(0)eξt+Λρμt0eξ(ts)E(s)ds. (8)

    Let X(t)=(I(t),C(t),S(t),P(t),E(t))T and then model (4) admits a unique disease-free ω-periodic solution

    X(t)=(0,C(t),S,P,E(t))T,

    where E(t) is defined as (6), and C(t),S(t),P(t) satisfy (7).

    Remark 1. If a(t)=0, i.e., the exogenous input rate of the AAP into the environment is zero, it follows that

    limtE(t)=limtE(t)=E0exp{t0η(s)ds}=0,limtC(t)=limt(C(0)eξt+ρt0eξ(ts)N(s)E(s)ds)=0,

    which implies that the AAP is eventually washed out of the environment in its totality. This agrees with our intuition. Of course, the time for this occurrence could be very long if the washout rate is small.

    The basic reproduction number R0 is the number of new infective individuals that are generated by a single infectious individual in a completely susceptible population. Now, we define the basic reproduction number R0. Thanks to [25,26], let F(t,X) be the input rate of newly infected individuals and V(t,X) be the rate of transfer of individuals. Then,

    F(t,X)=(λ(C)NSI0),V(t,X)=(μI+σIρNE+ξC).

    Then,

    F(t)=DF|X(t)=(β(t)(1+mC(t))S(t)S(t)+V(t)000),V(t)=DV|X(t)=(μ+σ00ξ).

    We can see that the eigenvalues of V are the diagonal elements and negative.

    Let Y(t,s),ts be the evolution operator of the linear ωperiodic system

    dYdt=V(t)y.

    That is, for each sR, the 2×2 matrix Y(t,x) satisfies

    {ddtY(t,s)=V(t)Y(t,s),ts,Y(s,s)=I,

    where I=diag(1,1) is the identity matrix. Following [27], let ϕ(s) be ω-periodic in s and the initial distribution of infectious individuals, so F(s)ϕ(s) is the rate of new infections produced by the infected individuals who are introduced at time s. When ts, Y(t,s)F(s)ϕ(s) gives the distribution of those infected individuals who are newly infected by ϕ(s) and remain in the infected compartments at time t. Naturally,

    tY(t,s)F(s)ϕ(s)ds=0Y(t,ta)F(ta)ϕ(ta)da

    is the distribution of accumulative new infections at time t produced by all those infected individuals ϕ(s) introduced at time previous to t.

    Let Cω be the ordered Banach space of all ω-periodic functions from R to R2, which is equipped with the maximum norm and the positive cone C+ω:={ϕCω:ϕ(t)0,tR}. Then, we define a linear operator L which implies that

    (Lϕ)(t)=0Y(t,ta)F(ta)ϕ(ta)da,tR,ϕCω,

    which is called the next infection operator, and the spectral radius of L is defined as the basic reproduction number

    R0:=ρ(L) (9)

    for the periodic epidemic model (4).

    Furthermore, we can obtain the global threshold dynamics of model (4).

    Theorem 2. If R0<1, model (4) admits a unique disease-free periodic solution X(t)=(0,C(t),S,V(t),E(t)) which is globally asymptotically stable, while if R0>1, it is unstable. If R0>1, there exists a positive constant ζ>0 such that for any initial values X(0)Γ, the solution of model (4) satisfies

    lim inftX(t)(ζ,ζ,ζ,ζ,ζ,ζ).

    That is, model (4) is uniformly persistent.

    The proof of Theorem 2 is standard, and we omit it here. We refer the reader to the proof of Theorem 3.9 in [28].

    We now focus on the influenza transmission dynamics of model (4) in a special case of β(t)=β,a(t)=a,η(t)=η. In this case, model (4) can be rewritten as follows:

    {dSdt=Λβ(1+mC)SINμSϕS+σ(1p)I+αP,dIdt=β(1+mC)SINμIσI,dPdt=ϕS+σpIμPαP,dCdt=ρNEξC,dEdt=aηE. (10)

    Model (10) always has a disease-free equilibrium (DFE) X=(0,C,S,V,E), where

    C=ρΛaμξη,S=Λ(μ+α)μ(α+μ+ϕ),V=Λϕμ(α+μ+ϕ),E=aη.

    The basic reproduction number ¯R0 of model (10) is

    ¯R0:=β(μ+α)(μ+α+ϕ)(μ+σ)+βΛ(μ+α)mρaμξη(μ+α+ϕ)(μ+σ). (11)

    If ¯R0>1, model (10) has an endemic equilibrium (EE) X=(I,C,S,V,E), where

    I=Λ(μ+α)(¯R01)μ(pσ+α+μ)¯R0,S=Λ(μ+α)μ(μ+α+ϕ)¯R0,P=Λ(pσ(¯R01)(μ+α)+ϕ(pσ¯R0+α+μ))μ¯R0(pσ+α+μ)(μ+α+ϕ),C=C=ρΛaμξη,E=E=aη.

    Three eigenvalues of the Jacobian matrix of model (10) at the endemic equilibrium X are μ,ξ,η, and the other two satisfy the following quadratic equation with respect to ζ:

    (pσ+α+μ)ζ2+(μ+α+ϕ)(μ¯R0+pσ+α+σ(¯R01))ζ+(¯R01)(μ+σ)(μ+α+ϕ)(pσ+α+μ)=0. (12)

    Obviously, the solutions of (12), ζ1,2, are less than 0, and hence the endemic equilibrium X of model (10) is locally asymptotically stable.

    Theorem 3. If R0>1, the endemic equilibrium X of model (10) is global asymptotically stable.

    Proof. In order to study the globally asymptotical stability of X, we consider

    {dNdt=ΛμN,dCdt=ρNEξC,dEdt=aηE.

    Then, N,C and E approach N,C and E as t, respectively. Asymptotically the second and third equations of model (10) can be rewritten as

    {dIdt=β(1+mC)(NIP)INμIσI,dPdt=ϕ(NIP)+σpIμPαP. (13)

    It follows that model (13) has an interior equilibrium ¯X=(I,P). Two eigenvalues of the Jacobian matrix of model (13) at ¯X satisfy (12). Hence ¯X is locally asymptotically stable.

    We now prove that model (13) has no periodic orbits. We choose the Dulac function

    B(I,P)=1IP.

    Let

    f(I,P)=β(1+mC)(NIP)INμIσI,g(I,P)=ϕ(NIP)+σpIμPαP.

    Then,

    I(Bf)+P(Bg)=β(1+mC)NPpσI+ϕ(NIP)IP2ϕIP<0.

    According to the Bendixson-Dulac criterion, model (13) has no periodic orbits, so the interior equilibrium ¯X=(I,P) is globally asymptotically stable, which completes the proof.

    In China, influenza has been classified as a class Ⅲ statutory reportable disease in the National Infectious Disease Reporting System. Hospitals and clinics collect nasopharyngeal swabs for each confirmed case, then send them to a designated laboratory for virus isolation and further identification and submits the result online within 24 h [17,29]. The data of ILI cases in Huaian city during the 1st week of 2019 (the data of 2019 is used for model simulation) to the 12th week of 2020 (the data of 2020 is used to test the model prediction) were derived from the Huaian Center for Disease Control and Prevention, which included information about ILI case number, vaccination number and the demographic data [30]. The ILI case is defined as a person with a sudden onset of fever (38C), chills, cough and/or sore throat, a generalized feeling of weakness and pain in the muscles, together with varying degrees of soreness in the head and abdomen. The information regarding the AAP was gathered from the China Online Air Quality Monitoring and Analysis Platform [31]. The details can be found in Figure 2.

    In model (4), E(t) is the concentration of the AAP in the environment. For studying the relations between ILI and the AAP (e.g., PM2.5, PM10, SO2, NO2, O3 and CO), we compute the Spearman's rank correlation coefficients between them.

    Spearman's correlation coefficient, the strength of the rank correlation between variables, is given by

    ρs:=16ni=1d2in(n21),

    where ni=1d2i represents the sum of the squared differences between x=(x1,x2,,xn) and y=(y1,y2,,yn) variable ranks, and n is the sample size.

    Form Table 2, we can see that the Spearman's rank correlation coefficients between PM2.5, PM10, SO2, NO2, O3, CO and ILI are 0.34, 0.40, 0.07, 0.02, -0.17, 0.56, respectively, which indicates that PM2.5, PM10, SO2, NO2 and CO are positively significantly correlated with the incidence of ILI, while O3 is negatively significantly correlated with the incidence of ILI. Noting that ρs of CO, PM10 and PM2.5 are the three largest Spearman's rank correlation coefficients, we choose CO, PM10 and PM2.5 as E(t) and focus on the effects of these factors on the prevalence of influenza in Huaian, China, respectively.

    Table 2.  Spearman's rank correlation coefficients between ILI and the AAP.
    PM2.5 PM10 SO2 NO2 O3 CO ILI
    PM25 1
    PM10 0.86 1
    SO2 0.60 0.36 1
    NO2 0.82 0.80 0.59 1
    O3 0.36 0.58 0.12 0.44 1
    CO 0.73 0.86 0.26 0.57 0.43 1
    ILI 0.34 0.40 0.07 0.02 0.17 0.56 1

     | Show Table
    DownLoad: CSV

    From the statistical data [30,31,32], we adopt

    Λ=50508,m=1010,μ=0.0128,σ=0.485,φ=0.365,α=0.15,p=0.275,ρ=0.001,ξ=0.5, (14)

    and the initial values are taken as S(0)=49,885, I(0=623, V(0)=0, C(0)=100.

    To parameterize the model, according to the statistical data of CO, PM10 and PM2.5 in Huaian, China [31], we use the Matlab function fminsearch with Nelder-Mead algorithm and estimate a(t) and η(t) via model (5).

    1) With ECO(0)=1.04, we can obtain

    aCO(t)=0.00630.0344sin(π26t+0.0197),ηCO(t)=0.0153sin(π26t).

    2) With EPM10(0)=107, we can obtain

    aPM10(t)=0.40798.2514sin(π26t0.1222),ηPM10(t)=0.0579sin(π26t).

    3) With EPM2.5(0)=76, we can obtain

    aPM2.5(t)=0.16080.7986sin(π26t+0.1389),ηPM2.5(t)=0.0525sin(π26t).

    Substitute the values above into model (4), respectively, and by using the Markov Chain Monte Carlo (MCMC) method, we can get

    1) βCO(t)=1.6131sin(0.0088t+0.9976).

    2) βPM10(t)=1.6135sin(0.0088t+0.9972).

    3) βPM2.5(t)=1.6135sin(0.0088t+0.9972).

    In numerical experiments, the weekly cumulative number of influenza cases and the values of CO, PM10 and PM2.5 of Huaian are respectively used to fit the number of infected cases. The model fits the reported cases in Huaian well generally (see Figure 4). Also, we find a decreasing trend in the projection results for the first twelve weeks in 2020 (see Figure 4). It should be noted that the model does not consider any interventions.

    Figure 4.  Fitting/Prediction model for the cumulative ILI cases for years 2019 and the first twelve weeks in 2020, respectively. The red dots are the reported number of ILI, the black line is the model fitting result, and the blue dotted line is the prediction result.

    To quantify the model's simulation and prediction performance, denoted by the error between the statistical data A=(a1,a2,,am) and the model values B=(b1,b2,,bm), we employ four statistical indices:

    1) the correlation coefficient (CC):

    CC:=mi=1(aiˉa)(biˉb)mi=1(aiˉa)2mi=1(biˉb)2,

    where ˉa=1mmi=1ai, ˉb=1mmi=1bi.

    2) absolute error (AE):

    AE:=1mmi=1(biai)=ˉbˉa.

    3) root mean square error (RMSE):

    RMSE:=1mmi=1(biai)2.

    4) the distance between indices of simulation and observation (DISO) [33,34,35]:

    DISO:=(ρ1)2+(AE/ˉa)2+(RMSE/ˉa)2.

    The performance is evaluated by the data from the 1st week of 2019 to the 12th week of 2020, and the results of CC, AE, RMSE and DISO are displayed in Tables 35, respectively.

    Table 3.  Evaluation results of the simulation and prediction of weekly cumulative ILI in Huaian, China, with CO.
    CC AE RMSE DISO
    Cumulative ILI cases 1.00 0.00 0.00 0.00
    Fitting model 0.999 -73.47 391.34 0.02
    Projection model 0.990 -797.09 2209.75 0.12

     | Show Table
    DownLoad: CSV
    Table 4.  Evaluation results of the simulation and prediction of weekly cumulative ILI in Huaian, China, with PM10.
    CC AE RMSE DISO
    Cumulative ILI cases 1.00 0.00 0.00 0.00
    Fitting model 0.999 -52.81 430.88 0.02
    Projection model 0.986 -761.5 2179.23 0.09

     | Show Table
    DownLoad: CSV
    Table 5.  Evaluation results of the simulation and prediction of weekly cumulative ILI in Huaian, China, with PM2.5.
    CC AE RMSE DISO
    Cumulative ILI cases 1.00 0.00 0.00 0.00
    Fitting model 0.999 -52.79 430.90 0.02
    Projection model 0.986 -61.52 2179.31 0.11

     | Show Table
    DownLoad: CSV

    Figure 4 and Tables 35 show that the fitting/predicting results of our model with CO, PM10 and PM2.5 have a certain reliability and rationality; hence, model (4) can well capture the history of influenza transmissions in Huaian, China.

    Furthermore, from Table 2, we can also know that PM2.5 is significantly related to CO and PM10, and the Spearman's rank correlation coefficients are 0.73 and 0.86, respectively. Hence, for simplicity, in the remainder, as an example, we only focus on the effect of PM2.5 on the spreading of influenza and the corresponding control measures.

    In this subsection, we will focus on the factors of controlling the prevalence of influenza. As an example, in Figure 5, we show the relations between the cumulative solutions of model (4) and parameters ϕ, σ and α. In Figure 5a, if we decrease ϕ=0.365 by 5%, i.e., ϕ decreases from ϕ to 0.95ϕ=0.34675, the solutions of model (4) increase; meanwhile, if we increase ϕ by 5%, i.e., ϕ increases from ϕ to 1.05ϕ=0.38325, the solutions of model (4) decrease. In Figure 5b, if we decrease σ=0.485 by 5%, i.e., σ decreases from ϕ to 0.95σ=0.46075, the solutions of model (4) increase; meanwhile, if we increase σ by 5%, i.e., σ increases from σ to 1.05σ=0.50925, the solutions of model (4) decrease. In Figure 5c, if we decrease α=0.15 by 10%, i.e., α decreases from α to 0.9α=0.135, the solutions of model (4) decrease; meanwhile, if we increase ϕ by 10%, i.e., α increases from α to 1.1α=0.165, the solutions of model (4) increase. Hence, in order to control the prevalence of influenza, we must increase the vaccination rate ϕ and the recovery rate σ and decrease the rate of the vaccine wearing off α.

    Figure 5.  The relations between the solutions of model (4) and parameters (a) ϕ, (b) σ, (c) α.

    In the fourth equation of model (4), parameters ρ and ξ are closely related to the effect of the AAP (e.g., PM2.5) on the incidence of ILI. The numerical results are shown in Figure 6. In Figure 6a, if we decrease ρ=1 by 50% and 75%, respectively, the solutions of model (4) decrease. In Figure 6b, if we decrease ξ=0.5 by 50%, i.e., α decreases from ξ to 0.5α=0.5, the solutions of model (4) increase; meanwhile, if we increase ξ by 50%, i.e., ξ increases from ξ to 1.5ξ=1.5, the solutions of model (4) decrease. These results show that the decrease of the uptake coefficient ρ and the increase of the depletion rate ξ are useful to control the spread of influenza.

    Figure 6.  The relations between the solutions of model (4) and parameters (a) ρ, (b) ξ, (c) m.

    On the other hand, in model (2), the term mC(t) describes the impact of the AAP (e.g., PM2.5) on the transmission rate. In Figure 6c, we show the relations between the solutions of model (4) with m. Obviously, m>0 increases the values of transmission rate λ(C), which results in increases in the solutions of model (4). In addition, when increasing m=1010 by 50%, i.e., m increases from m to 1.5×1010, the solutions of model (4) increase. Hence, the decrease of PM2.5 (measured by m) can efficiently suppress the influenza outbreak.

    It is widely known that the transmission rate β(t)=b1sin(b2t+b3) plays an important role in epidemic model (4), where b1 is called the baseline rate. In Figure 7, we give the relations between the cumulative solutions of model (4) with the baseline rate b1, which shows that the cumulative influenza cases increase with the increase of b1, and the decrease of the baseline rate b1 is beneficial to controlling the incidence of influenza.

    Figure 7.  The relations between the solutions of model (4) and the baseline rate b1.

    It is now widely believed that ambient particulate air pollution is a key factor in the incidence of influenza. More different from existing research [3,4,13,14,15,16,17,18], in this work, we have derived an AAP-dependent dynamical model that incorporates partial immunity and vaccination, and the infection rate with an AAP-dependent linear effect, and we proved that the basic reproduction number R0 can be used to govern the threshold dynamics of model (4): If R0<1, the influenza disease will go extinct, while if R0>1, model (4) is uniformly persistent, i.e., the influenza disease is always endemic. Based on the statistical data, via numerical simulations, we find that, in order to control the prevalence of influenza in Huaian, China, we must raise the vaccination rate ϕ (see Figure 5(a)) and the recovery rate σ (see Figure 5(b)) and reduce the rate of the vaccine wearing off α (see Figure 5(c)), the uptake coefficient ρ (see Figure 6(a)), the depletion rate ξ (see Figure 6(b)), the effect coefficient of the AAP on transmission rate m (see Figure 6(c)) and the baseline rate b1 (see Figure 7). The theoretical and numerical results show that the dynamics of model (4) provides a profile of the prevalence of influenza in Huaian, China and gives us some useful information of controlling the influenza.

    It is worthy to note that, decreasing/increasing the values of the parameters in model (4) or model (10) is complex system engineering, involving the government's intervention strategies and human behavior. In reality, what we can do is change our behavior, especially, changing our traveling plan and staying at home to reduce the contact rate β(t) and thus decrease the incidence rate λ(C), or increase the close-contact distance and wear protective masks to reduce the influence of the AAP (measured by m) on the influenza transmission.

    The authors would like to thank the anonymous referees for helpful suggestions and comments which led to improvements of the original manuscript. This research was supported by the National Natural Science Foundation of China (Grant numbers 12071173 and 12171192) and Huaian Key Laboratory for Infectious Diseases Control and Prevention (HAP201704).

    The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



    Conflict of interest



    The authors confirm that there is no conflict of interest.

    [1] Davidson H (2020)  First Covid-19 case happened in November, China government records show – report. Available from: https://www.theguardian.com/world/2020/mar/13/first-covid-19-case-happened-in-november-china-government-records-show-report.
    [2] Lam TT, Shum MH, Zhu H, et al. (2020) Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature 583: 282-285. doi: 10.1038/s41586-020-2169-0
    [3]  World Health Organization, Coronavirus disease (COVID-19) pandemic, 2020. Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    [4]  COVID-19 coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus/.
    [5] Hirji Z (2020)  Thousands Of US Health Care Workers Have Been Infected By The Coronavirus. This Is How Each State Stacks Up. Available from: https://www.buzzfeednews.com/article/zahrahirji/us-health-care-workers-coronavirus.
    [6] Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses New York, NY: Humana Press, 1-23.
    [7] Wu F, Zhao S, Yu B, et al. (2020) A new coronavirus associated with human respiratory disease in China. Nature 579: 265-269. doi: 10.1038/s41586-020-2008-3
    [8] Kahn JS, McIntosh K (2005) History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24: S223-S227. doi: 10.1097/01.inf.0000188166.17324.60
    [9] Bernama (2020)  Pets found positive for Covid-19 must be quarantined. Available from: www.nst.com.my/news/nation/2020/04/582666/pets-found-positive-covid-19-must-be-quarantined.
    [10]  Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations, 2020. Availble from: www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations.
    [11] Zeng ZQ, Chen DH, Tan WP, et al. (2018) Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China. Eur J Clin Microbiol Infect Dis 37: 363-369. doi: 10.1007/s10096-017-3144-z
    [12] Van Hemert MJ, van den Worm SH, Knoops K, et al. (2008) SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog 4: e1000054. doi: 10.1371/journal.ppat.1000054
    [13] Chan JFW, Kok KH, Zhu Z, et al. (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes Infect 9: 221-236. doi: 10.1080/22221751.2020.1719902
    [14] Sola I, Mateos-Gomez PA, Almazan F, et al. (2011) RNA-RNA and RNA-protein interactions in coronavirus replication and transcription. RNA Biol 8: 237-248. doi: 10.4161/rna.8.2.14991
    [15] Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5
    [16] Chen T, Wu D, Chen H, et al. (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: a retrospective study. BMJ 368: m1091. doi: 10.1136/bmj.m1091
    [17] Liu W, Li H (2020)  COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. Available from https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173.
    [18] Cascella M, Rajnik M, Cuomo A, et al. (2020) Features, evaluation and treatment coronavirus (COVID-19). StatPearls Treasure Island (FL): StatPearls Publishing.
    [19] Conger K COVID-19 patients often infected with other respiratory viruses, preliminary study reports. Available from: https://med.stanford.edu/news/all-news/2020/03/covid-19-can-coexist-with-other-respiratory-viruses.html.
    [20] Cheng Y, Luo R, Wang K, et al. (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97: 829-838. doi: 10.1016/j.kint.2020.03.005
    [21] O'Connor E, The J, Kamat AM, et al. (2020) Bacille Calmette-Guérin (BCG) vaccination and COVID-19. Future Oncol 16: 1323-1325. doi: 10.2217/fon-2020-0381
    [22] ClinicalTrials.gov, Bethesda (MD): National Library of Medicine (US), 2020 Feb 18 – Identifier NCT01067417, Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune activation in asymptomatic HIV-infected patients (HCQ01).Available from: https://clinicaltrials.gov/ct2/show/NCT01067417.
    [23] Gautret P, Lagier JC, Parola P, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949.
    [24] Matsuoka K (2020)  Fujifilm tests favipiravir as a COVID-19 treatment. Available from: https://cen.acs.org/pharmaceuticals/drug-development/Fujifilm-tests-favipiravir-COVID-19/98/i15.
    [25] Tu YF, Chien CS, Yarmishyn AA, et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci 21: 2657. doi: 10.3390/ijms21072657
    [26]  A promising COVID-19 treatment gets fast-tracked. Available from: https://hub.jhu.edu/2020/04/08/arturo-casadevall-blood-sera-profile/.
    [27]  Trial drug may block early stages of COVID-19, study in human cells shows. Available from: https://news.ki.se/trial-drug-may-block-early-stages-of-covid-19-study-in-human-cells-shows.
    [28] Jokinen C, Heiskanen L, Juvonen H, et al. (2001) Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis 32: 1141-1154. doi: 10.1086/319746
    [29]  Coronavirus disease COVID-19. available from https://www.pluristem.com/coronavirus-disease-covid-19/.
    [30] ClinicalTrials.gov, Bethesda (MD): National Library of Medicine (US). 2020 Mar 12 – Identifier NCT04261426, The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV infected pneumonia.Available from: https://clinicaltrials.gov/ct2/show/NCT04261426.
    [31] ClinicalTrials.gov, Bethesda (MD): National Library of Medicine (US). 2020 Mar 12 – Identifier NCT04293887, Efficacy and safety of IFN-α2β in the treatment of novel coronavirus patients.Available from: https://clinicaltrials.gov/ct2/show/NCT04293887?term=NCT04293887&draw=2&rank=1.
    [32] ClinicalTrials.gov, Bethesda (MD): National Library of Medicine (US). 2020 Mar 12 – Identifier NCT04273581, The efficacy and safety of thalidomide combined with low-dose hormones in the treatment of severe Covid-19.Available from: https://clinicaltrials.gov/ct2/show/NCT04273581?term=NCT04273581&draw=2&rank=1.
    [33] Long Y, Xu Y, Wang B, et al. (2016) Clinical recommendations from an observational study on MERS: Glucocorticoids was benefit in treating SARS patients. Int J Clin Exp Med 9: 8865-8873.
    [34] Devin H Lessons from SARS outbreak help in race for coronavirus vaccine. Available from: https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine.
    [35] Saskatchewan lab joins global effort to develop coronavirus vaccine. The Canadian Press, 2020.Available from: https://www.cbc.ca/news/canada/saskatchewan/vido-intervac-working-on-coronavirus-vaccine-1.5439118.
    [36] MIGAL's coronavirus vaccine project.Available from: http://www.migal.org.il/en/node/7010.
    [37] China coronavirus: Hong Kong researchers have developed coronavirus vaccine, expert reveals.Available from: https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have.
    [38]  Vaxart (VXRT) - A long shot or perfect shot?. Available from: https://www.nasdaq.com/articles/vaxart-vxrt-a-long-shot-or-perfect-shot-2020-02-25.
    [39] Wash U Scientists Are Developing A Coronavirus Vaccine.Available from: https://news.stlpublicradio.org/post/wash-u-scientists-are-developing-coronavirus-vaccine#stream/0.
    [40] Emergent BioSolutions dives into another coronavirus vaccine effort.Available from: https://www.bizjournals.com/washington/news/2020/03/18/emergent-biosolutions-dives-into-another.html.
    [41] Will take one-and-a-half to two years for India to develop a vaccine for COVID-19: Health Ministry.Available from: https://economictimes.indiatimes.com/news/politics-and-nation/will-take-one-and-a-half-to-two-years-for-india-to-develop-vaccine-for-covid-19-health-ministry/articleshow/74597044.cms?from=mdr.
    [42] Coronavirus: Commission offers financing to innovative vaccines company CureVac. European Commission.Available from: https://ec.europa.eu/commission/presscorner/detail/en/IP_20_474.
    [43] Pfizer and BioNTech announce joint development of a potential COVID-19 vaccine.Available from: https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-to-Co-Develop-Potential-COVID-19-Vaccine/default.aspx.
    [44] CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine. Coalition for Epidemic Preparedness Innovations.Available from: https://www.pasteur.fr/en/press-area/press-documents/cepi-collaborates-institut-pasteur-consortium-develop-covid-19-vaccine.
    [45] Russia starts testing coronavirus vaccine prototypes on animals.Available from: https://www.reuters.com/article/us-health-coronavirus-russia-tests/russia-starts-testing-coronavirus-vaccine-prototypes-on-animals-idUSKBN2170PP.
    [46] Millions of chickens are used to make vaccines each year. But that won't work for coronavirus.Available from: https://edition.cnn.com/2020/03/27/health/chicken-egg-flu-vaccine-intl-hnk-scli/index.html.
    [47] World Health Organization, the Draft landscape of COVID-19 candidate vaccines, 2020.Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
  • This article has been cited by:

    1. Xiaoyan Zheng, Qingquan Chen, Mengcai Sun, Quan Zhou, Huanhuan Shi, Xiaoyang Zhang, Youqiong Xu, Exploring the influence of environmental indicators and forecasting influenza incidence using ARIMAX models, 2024, 12, 2296-2565, 10.3389/fpubh.2024.1441240
  • Reader Comments
  • © 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(4536) PDF downloads(257) Cited by(10)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog